NCT07398651Not yet recruiting
Apremilast and Adalimumab in Psoriatic Arthritis Patients
Comparative Study Between Apremilast and Adalimumab in Psoriatic Arthritis Patients
Source: ClinicalTrials.gov · Last updated 8 Sept 2026
Brief summary (registry, in English)
The aim of this work is to compare the efficacy of Apremilast combined with Methotrexate versus Adalimumab combined with Methotrexate
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 29 Jan 2026
- Start date
- 30 Dec 2026
- Primary completion date
- 30 Dec 2026
- Lead sponsor
- Tanta University
- Diseases
- Psoriasis, Psoriatic arthritis
- NCT number
- NCT07398651
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 30 Dec 2026 to the primary completion date, 30 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who received previous biologic agents or Janus kinase inhibitors.
Other illness
- Current or recent serious infection including tuberculosis or hepatitis B/C .
- Current or past history of malignancy (within five year).
Lab values
- Severe uncontrolled comorbidities such as heart failure, severe liver disease, or chronic kidney disease (eGFR \<30 mL/min/1.73m²) .
Other
- Patients with axial and ocular involvement.
- Pregnant or breastfeeding women or women planning pregnancy during the study period .
Who the study is looking for
- This study will include 60 adult Psoriatic arthritis patients \>18 years old, fulfilling the (CASPAR) classification criteria of Psoriatic arthritis and have an inadequate response to methotrexate therapy for at least 3 months.
- Psoriatic arthritis patients with peripheral musculoskeletal domains (peripheral arthritis, dactylitis and enthesitis) as well as skin and nail domains
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tanta university Coordinator of this site? Confirm its status | Tanta | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.